Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer (vol 76, pg 925, 2015)

被引：0
|
作者：
Bendell, Johanna C. [1 ]
Rosen, Lee S. [2 ]
Mayer, Robert J. [3 ]
Goldman, Jonathan W. [2 ]
Infante, Jeffrey R. [1 ]
Benedetti, Fabio [4 ]
Lin, Donghu [5 ]
Mizuguchi, Hirokazu [4 ]
Zergebel, Christopher [4 ]
Patel, Manish R. [6 ]
机构：
[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, 250 25th Ave North,Suite 200, Nashville, TN 37203 USA
[2] Univ Calif, 2020 Santa Monica Blvd,Suite 600, Santa Monica, CA 90404 USA
[3] Dana Farber Canc Inst, 450 Brookline Ave,Dana 1602, Boston, MA 02215 USA
[4] Taiho Oncol Inc, 202 Carnegie Ctr,Suite 100, Princeton, NJ 08540 USA
[5] Taiho Pharmaceut Beijing Co Ltd, 9F-9A3,Hanwei Plaza,7th,Guanghua Rd, Beijing 100004, Peoples R China
[6] Sarah Cannon Res Inst, Florida Canc Specialists, 600 N Cattlemen Rd,Suite 200, Sarasota, FL 34232 USA
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2016年 / 77卷 / 02期
关键词：
D O I：
10.1007/s00280-015-2890-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：439 / 439
页数：1
相关论文
共 50 条
  • [21] Retrospective analysis of TAS-102 for metastatic colorectal cancer
    Aoki, M.
    Shimamoto, F.
    Ikegami, T.
    Yamaguchi, T.
    Terazawa, T.
    Kii, T.
    Goto, M.
    Higuchi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] TAS-102 plus bevacizumab in metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    LANCET ONCOLOGY, 2020, 21 (05): : E226 - E226
  • [23] A novel antimetabolite: TAS-102 for metastatic colorectal cancer
    Miyamoto, Yuji
    Lenz, Heinz-Josef
    Baba, Hideo
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 355 - 365
  • [24] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [25] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    BMC Gastroenterology, 21
  • [26] A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Lee, Valerie
    Parkinson, Rose
    Zahurak, Marianna
    Cope, Leslie
    Cercek, Andrea
    Verheul, Henk
    Gootjes, Elske
    Lenz, Heinz Josef
    Iqbal, Syma
    Jones, Peter
    Baylin, Stephen
    Rami, Vandna
    Ahuja, Nita
    El Khoueiry, Anthony
    Azad, Nilofer S.
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (10) : 1794 - 1801
  • [27] A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE)
    Taniguchi, H.
    Narita, Y.
    Kadowaki, S.
    Ura, T.
    Ando, M.
    Muro, K.
    Hamauchi, S.
    Tsushima, T.
    Yokota, T.
    Todaka, A.
    Machida, N.
    Fukutomi, A.
    Onozawa, Y.
    Yasui, H.
    Mori, K.
    Yamazaki, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Komori, Azusa
    Kito, Yosuke
    Mitani, Seiichiro
    Hasegawa, Hiroko
    Narita, Yukiya
    Kadowaki, Shigenori
    Ura, Takashi
    Ando, Masashi
    Mori, Keita
    Tajika, Masahiro
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
    Chen, Duke
    Wu, Yu-Shen
    Lin, Huapeng
    Wang, Yihan
    Li, Longhao
    Zhang, Tao
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2915 - 2924
  • [30] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AND TAS-102 IN REFRACTORY METASTATIC COLORECTAL CANCER
    Cho, S. K.
    Hay, J. W.
    Barzi, A.
    VALUE IN HEALTH, 2018, 21 : S1 - S1
12345